A recent review emphasizes the need for personalized treatment strategies and a multidisciplinary approach to effectively ...

Irina Dralyuk, MD, discusses how to best prevent vulnerable parties, especially children, from breathing in the toxic smoke in Los Angeles.

Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support ...

Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge ...

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world ...

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...

Throughout 2024, the Center on Health Equity & Access explored critical gaps in health care access and innovative efforts to address them.

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific ...

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or ...

Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the ...